Pharmaceuticals, Biotechnology and Life Sciences
Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines Catalent will continue to…
Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines Catalent will continue to…
Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines Catalent will continue to…
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Gastrointestinal Stromal Tumor (GIST)” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers…
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Uterine Cancer” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the uterine…
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Uterine Cancer” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the uterine…
LYNPARZA is the Only PARP Inhibitor Approved in Japan KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck (NYSE: MRK), known as MSD…
Estimation says that in 2017, there were approximately 19,950
incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and
forecasts that number to increase to 23,880 incident cases by 2026.
Therapeutics Market by type (antiprotozoal therapeutics, anthelminthic
therapeutics, scabicides, and pediculicides therapeutics) and geographic
regions (Asia, ROW, North America, and Europe) is witnessed to
grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”
– Phase IIIb study met all primary and secondary endpoints
with statistical significance and demonstrated that linaclotide improved
the overall abdominal symptoms of bloating, pain and discomfort in
adults with IBS-C –